To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to evaluate the effectiveness and safety of Afininib compared to
irinotecan in the 3-gene RNA sequencing (ALTRK) negative advanced esophageal squamous
squamous carcinoma.